Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Single centre recruiting approximately 80 patients who are given a rising single, followed by
multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in
patients with solid tumors and metastatic liver disease.